Why Onto Innovation ONTO earnings beat or miss matters less than you think Onto Innovation Misses Estimates as Demand Cools VERX Vertex posts narrow Q4 2025 EPS beat shares fall nearly 3 percent amid muted investor sentiment The real story behind The Beauty SKIN valuation Slight Dip 20260508 How will Century Therapeutics IPSC earnings compare to expectations Q4 2025 Better Than Expected